Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
07:00am, Thursday, 09'th Nov 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthca
GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript
12:24pm, Friday, 03'rd Nov 2023
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
07:00am, Friday, 03'rd Nov 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
07:00am, Friday, 20'th Oct 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
07:00am, Wednesday, 06'th Sep 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Tuesday, 05'th Sep 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Co
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 17'th Aug 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on August
GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript
01:09pm, Wednesday, 02'nd Aug 2023
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - CMO Bria
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
07:00am, Wednesday, 19'th Jul 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, Augus
GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy
08:02am, Tuesday, 30'th May 2023
GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and techni
GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology
12:20pm, Wednesday, 10'th May 2023
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and the
GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call Transcript
11:09am, Wednesday, 29'th Mar 2023
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chie
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
07:00am, Thursday, 16'th Mar 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on We
GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity
11:20pm, Wednesday, 08'th Mar 2023
Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients should
